Peptide InjectionsAI
High evidence

Cagrilintide + Semaglutide

Peptide therapy: benefits, side effects, cost and protocols

CagriSema is a combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) being developed by Novo Nordisk. The dual mechanism targets both amylin and GLP-1 pathways for potentially greater weight loss than either agent alone.

ByChris Riley(CFA)|Updated

Sources: FDA / PubMed / ClinicalTrials.gov View

FDA status
Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
Evidence
Strong Evidence

Who Cagrilintide + Semaglutide is usually considered for

  • Enhanced weight management
  • Dual mechanism approach
  • Appetite control

How Cagrilintide + Semaglutide works

Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.

Key studies

85 papers on PubMed / 54 human trials

  1. 01

    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

  2. 02

    Garvey WT, Blüher M, Osorto Contreras CK et al

    N Engl J Med / Phase 3

    Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo.

  3. 03

    Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo

  4. 04

    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

  5. 05

    Davies MJ, Bajaj HS, Broholm C et al

    N Engl J Med / Phase 3

    Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% with placebo in type 2 diabetes.

  6. 06

    Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% with placebo in type 2 diabetes

  7. 07

    Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials

  8. 08

    El-Sheikh M, Sillassen CDB, Wisborg FD et al

    BMJ Open

  9. 09

    Protocol for systematic review of cardiovascular effects of incretin-based drugs in heart failure patients

  10. 10

    Incretin-based therapies for the treatment of obesity-related diseases

Cagrilintide + Semaglutide questions

What is CAGRILINTIDE + SEMAGLUTIDE?

A dual-action combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist) being researched for enhanced weight management effects through complementary mechanisms.

How does CAGRILINTIDE + SEMAGLUTIDE work?

Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.

Is CAGRILINTIDE + SEMAGLUTIDE legal to buy?

CAGRILINTIDE + SEMAGLUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy CAGRILINTIDE + SEMAGLUTIDE?

CAGRILINTIDE + SEMAGLUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does CAGRILINTIDE + SEMAGLUTIDE belong to?

CAGRILINTIDE + SEMAGLUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of CAGRILINTIDE + SEMAGLUTIDE?

CAGRILINTIDE + SEMAGLUTIDE has been studied for: Enhanced weight management, Dual mechanism approach, Appetite control. Dual-action blend targeting multiple metabolic pathways.

Cagrilintide + Semaglutide in the news

News aggregated via Google News. Inclusion does not imply endorsement.

Considering Cagrilintide + Semaglutide?

The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.

Take the quiz